Form 4: Lynx1 Capital Boosts Cullinan Therapeutics Stake

Lynx1 Capital Management LP and Weston Nichols increased their beneficial ownership in Cullinan Therapeutics, Inc. through multiple common stock purchases in mid-October 2025.

Summary

• Lynx1 Capital Management LP and Weston Nichols, identified as a 10% owner and director of Cullinan Therapeutics, Inc. (CGEM), acquired additional shares of common stock.
• The transactions occurred between October 14, 2025, and October 17, 2025.
• A total of 248,749 shares of common stock were purchased across four separate transactions.
• The purchases were made at weighted average prices ranging from $7.587 to $8.855 per share.
• Following these transactions, the beneficial ownership of common stock by the reporting persons increased to 8,797,833 shares.
• The securities are held indirectly by Lynx1 Master Fund LP, for which Lynx1 Capital Management LP serves as investment manager.
• Weston Nichols is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager.
• The transactions were made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to significant insider buying by a 10% owner and director, indicating strong confidence in the company's valuation and future prospects.

Positives

• Increased insider ownership by a 10% owner and director signals strong confidence in the company's future prospects.
• The significant volume of shares purchased (248,749 shares) demonstrates a substantial commitment from the reporting persons.
• Purchases made under a Rule 10b5-1 plan indicate a pre-planned investment strategy, potentially reducing concerns about opportunistic timing.

Future Outlook

This filing reports past transactions and does not contain forward-looking statements or guidance from the company.

Management Comments

• Lynx1 Capital Management LP and Weston Nichols disclaim beneficial ownership of the securities for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of their pecuniary interest therein, if any.

Industry Context

Insider buying, particularly by significant shareholders and directors, is often interpreted by the market as a positive signal, suggesting that those with intimate knowledge of the company believe its stock is undervalued or that positive developments are anticipated. This activity in the biotechnology sector can be particularly impactful, as company-specific news often drives stock performance.

Stakeholder Impact

• Shareholders may view the increased insider ownership as a positive indicator of management and significant investor confidence, potentially leading to increased investor interest and a positive impact on share price.
• Employees may perceive this as a sign of stability and positive outlook for the company.

Key Dates

Recommendation

The substantial increase in beneficial ownership by a 10% owner and director, Lynx1 Capital Management LP and Weston Nichols, signals strong conviction in Cullinan Therapeutics' future. Insider buying is generally considered a bullish indicator, suggesting that those with the most intimate knowledge of the company believe its shares are undervalued or that significant positive developments are on the horizon. This action, especially when executed under a 10b5-1 plan, implies a strategic and confident investment, making the stock an attractive 'buy' for investors seeking to align with informed insider sentiment.

Keywords

Cullinan Therapeutics, CGEM, Lynx1 Capital Management, Weston Nichols, Insider Buying, Form 4, Beneficial Ownership, Stock Purchase, Biotechnology, Pharmaceuticals